{"entity":{"id":"nct04114825","kind":"trial","name":"Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer","aka":[],"tldr":"A phase 2 trial of RV001V in prostate cancer, run by RhoVac APS, active and no longer recruiting.","summary":"Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer is a phase 2 interventional study registered as NCT04114825 by RhoVac APS, with 180 participants enrolled, started 2019-11-19 and due to reach its primary completion in 2022-04. Interventions recorded: RV001V.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04114825","url":"https://clinicaltrials.gov/study/NCT04114825"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04114825","phase":"2","setting":"A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)","sponsor":"RhoVac APS","enrolled":180,"outcomes":[]},"route":"/trials/nct04114825/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"rv001v","kind":"drug","name":"RV001V","route":"/drugs/rv001v/"}]}}